** Shares of therapy developer Marinus Pharmaceuticals
fall ~61.5% to 65 cents premarket
** Co says it is discontinuing development of its oral drug ganaxolone after it missed the main goal in a late-stage trial in patients with a rare genetic brain disease called tuberous sclerosis complex (TSC)
** MRNS says the drug did not show a significant reduction in frequency of TSC-associated seizures
** Co says it is exploring strategic alternatives and is taking additional steps to reduce costs, including a reduction in its workforce
** Up to last close, stock down 84.5% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.